Defence Therapeutics Inc. has announced a significant milestone in its radio-immuno-conjugates project.
The Canadian Nuclear Research Initiative Health (CNRI-H) Program application by Defence Therapeutics has been approved by...
Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with...
Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer...